cnbc.com
🌐 75% Global Worthiness
Danaher's 2024 Challenges and 2025 Outlook
Danaher, a life sciences firm, faced a difficult 2024 due to reduced bioprocessing demand from high customer inventories and underfunded biotech startups, compounded by China's economic slowdown; however, a 2025 rebound is anticipated from increased IPO activity and normalized inventories.
Danaher's 2024 Challenges and 2025 Outlook
Danaher, a life sciences firm, faced a difficult 2024 due to reduced bioprocessing demand from high customer inventories and underfunded biotech startups, compounded by China's economic slowdown; however, a 2025 rebound is anticipated from increased IPO activity and normalized inventories.
Progress
40% Bias Score
Decent Work and Economic Growth